About Response Genetics (OTCMKTS:RGDXQ)
Response Genetics, Inc. is a life science company. The Company is engaged in the research, development, marketing and sale of pharmacogenomic tests for use in the treatment of cancer. To generate pharmacogenomic information from patient specimens for these tests, the Company uses its own methods for the extraction and analysis of nucleic acids and accessing the genetic information available from each patient sample. The Company's platforms include analysis of single biomarkers using the polymerase chain reaction method, as well as gene interrogation using microarray methods and fluorescence in situ hybridization (FISH) from paraffin or frozen tissue specimens. The Company is engaged in selling ResponseDX diagnostic testing products. The Company provides pharmacogenomic clinical trial testing services to pharmaceutical companies in the United States, Asia and Europe.
Industry, Sector and Symbol
Industry Medical Laboratories & Research
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Response Genetics (OTCMKTS:RGDXQ) Frequently Asked Questions
What is Response Genetics' stock symbol?
Response Genetics trades on the OTCMKTS under the ticker symbol "RGDXQ."
How were Response Genetics' earnings last quarter?
Response Genetics, Inc. (OTCMKTS:RGDXQ) issued its quarterly earnings results on Tuesday, March, 31st. The medical research company reported ($0.09) EPS for the quarter. The medical research company had revenue of $4.10 million for the quarter. View Response Genetics' Earnings History.
Who are some of Response Genetics' key competitors?
Some companies that are related to Response Genetics include NephroGenex (NRXGQ), School Specialty (SCHSQ), TranSwitch (TXCCQ), Local (LOCMQ), Body Central (BODY), Alco Stores (ALCSQ), Shale Oil International (SHLE), New Western Energy (NWTR), Circle Star Energy (CRCL), DS Healthcare Group (DSKX), ITT Educational Services (ESINQ), CTPartners Executive Search (CTPR), Alexza Pharmaceuticals (ALXA), Altice S A (ATCEY), AMS (AMSSY), ATP Oil & Gas (ATPAQ), BG Group (BRGYY) and BPZ Resources (BPZRQ).
Who are Response Genetics' key executives?
Response Genetics' management team includes the folowing people:
- Thomas A. Bologna, Chairman of the Board, Chief Executive Officer (Age 66)
- Kevin Roy Harris, Chief Financial Officer, Vice President (Age 47)
- Adanech Getachew, General Counsel (Age 37)
- Kirk K. Calhoun, Lead Independent Director (Age 73)
- Michael Serruya, Director (Age 51)
- Sam Chawla, Independent Director (Age 41)
- David R Schreiber, Independent Director (Age 55)
- Richard A. van den Broek, Independent Director (Age 49)
How do I buy Response Genetics stock?
Shares of Response Genetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Response Genetics' stock price today?
One share of Response Genetics stock can currently be purchased for approximately $0.00.
How big of a company is Response Genetics?
Response Genetics has a market capitalization of $20,000.00.
How can I contact Response Genetics?
Response Genetics' mailing address is 1640 MARENGO ST 7TH FLOOR, LOS ANGELES CA, 90033. The medical research company can be reached via phone at 323-224-3900 or via email at [email protected]
MarketBeat Community Rating for Response Genetics (RGDXQ)MarketBeat's community ratings are surveys of what our community members think about Response Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Response Genetics (OTCMKTS:RGDXQ) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Response Genetics (OTCMKTS:RGDXQ) Earnings History and Estimates Chart
Response Genetics (OTCMKTS RGDXQ) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/14/2015||Q115||($0.10)||$3.90 million||$3.80 million||View||Listen|
|11/13/2014||Q3 2014||($0.09)||$4.47 million||View||N/A|
|8/14/2014||Q214||($0.08)||$3.90 million||$4.30 million||View||N/A|
|5/8/2014||Q114||($0.06)||($0.03)||$5.50 million||$3.90 million||View||N/A|
|3/20/2014||Q413||($0.07)||($0.09)||$5.30 million||$4.80 million||View||N/A|
|11/7/2013||Q313||($0.07)||($0.08)||$5.40 million||$4.10 million||View||N/A|
|8/8/2013||Q2 2013||($0.04)||($0.11)||$5.40 million||$5.30 million||View||N/A|
|5/14/2013||Q1 2013||($0.04)||($0.03)||$4.92 million||$5.60 million||View||N/A|
|11/13/2012||Q312||($0.07)||($0.05)||$4.50 million||$5.40 million||View||N/A|
Response Genetics (OTCMKTS:RGDXQ) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Response Genetics (OTCMKTS:RGDXQ)
No dividend announcements for this company have been tracked by MarketBeat.com
Response Genetics (OTCMKTS RGDXQ) News Headlines
Response Genetics (OTCMKTS:RGDXQ) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Response Genetics (OTCMKTS RGDXQ) Stock Chart for Thursday, February, 22, 2018